833 related articles for article (PubMed ID: 10919897)
1. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
Alexandrakis G; Alfonso EC; Miller D
Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
[TBL] [Abstract][Full Text] [Related]
2. Shifting trends in bacterial keratitis in Toronto: an 11-year review.
Lichtinger A; Yeung SN; Kim P; Amiran MD; Iovieno A; Elbaz U; Ku JY; Wolff R; Rootman DS; Slomovic AR
Ophthalmology; 2012 Sep; 119(9):1785-90. PubMed ID: 22627118
[TBL] [Abstract][Full Text] [Related]
3. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.
Goldstein MH; Kowalski RP; Gordon YJ
Ophthalmology; 1999 Jul; 106(7):1313-8. PubMed ID: 10406613
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic resistance in microbial keratitis: ten-year experience of corneal scrapes in the United Kingdom.
Shalchi Z; Gurbaxani A; Baker M; Nash J
Ophthalmology; 2011 Nov; 118(11):2161-5. PubMed ID: 21764458
[TBL] [Abstract][Full Text] [Related]
5. Microbial keratitis in Waikato, New Zealand.
Pandita A; Murphy C
Clin Exp Ophthalmol; 2011 Jul; 39(5):393-7. PubMed ID: 21176039
[TBL] [Abstract][Full Text] [Related]
6. Microbial keratitis in los angeles: the doheny eye institute and the los angeles county hospital experience.
Sand D; She R; Shulman IA; Chen DS; Schur M; Hsu HY
Ophthalmology; 2015 May; 122(5):918-24. PubMed ID: 25600200
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones.
Chawla B; Agarwal P; Tandon R; Titiyal JS; Sharma N; Agarwal T; Navak N; Satpathy G
Eur J Ophthalmol; 2010; 20(2):300-5. PubMed ID: 19924668
[TBL] [Abstract][Full Text] [Related]
8. Seasonal, geographic, and antimicrobial resistance patterns in microbial keratitis: 4-year experience in eastern Pennsylvania.
Ni N; Nam EM; Hammersmith KM; Nagra PK; Azari AA; Leiby BE; Dai Y; Cabrera FA; Ma JF; Lambert CE; Honig SE; Rapuano CJ
Cornea; 2015 Mar; 34(3):296-302. PubMed ID: 25603231
[TBL] [Abstract][Full Text] [Related]
9. Trends in Microbiological and Antibiotic Sensitivity Patterns in Infectious Keratitis: 10-Year Experience in Mexico City.
Hernandez-Camarena JC; Graue-Hernandez EO; Ortiz-Casas M; Ramirez-Miranda A; Navas A; Pedro-Aguilar L; Lopez-Espinosa NL; Gaona-Juarez C; Bautista-Hernandez LA; Bautista-de Lucio VM
Cornea; 2015 Jul; 34(7):778-85. PubMed ID: 25811724
[TBL] [Abstract][Full Text] [Related]
10. Bacterial Keratitis in Toronto: A 16-Year Review of the Microorganisms Isolated and the Resistance Patterns Observed.
Tam ALC; Côté E; Saldanha M; Lichtinger A; Slomovic AR
Cornea; 2017 Dec; 36(12):1528-1534. PubMed ID: 28938380
[TBL] [Abstract][Full Text] [Related]
11. Shifting Trends in Bacterial Keratitis in Taiwan: A 10-Year Review in a Tertiary-Care Hospital.
Hsiao CH; Sun CC; Yeh LK; Ma DH; Chen PY; Lin HC; Tan HY; Chen HC; Chen SY; Huang YC
Cornea; 2016 Mar; 35(3):313-7. PubMed ID: 26764878
[TBL] [Abstract][Full Text] [Related]
12. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin.
Ly CN; Pham JN; Badenoch PR; Bell SM; Hawkins G; Rafferty DL; McClellan KA
Clin Exp Ophthalmol; 2006; 34(1):44-50. PubMed ID: 16451258
[TBL] [Abstract][Full Text] [Related]
13. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones in the treatment of bacterial keratitis.
Bower KS; Kowalski RP; Gordon YJ
Am J Ophthalmol; 1996 Jun; 121(6):712-5. PubMed ID: 8644818
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance trends in bacterial keratitis over 5 years in Sydney, Australia.
Cabrera-Aguas M; Khoo P; George CRR; Lahra MM; Watson SL
Clin Exp Ophthalmol; 2020 Mar; 48(2):183-191. PubMed ID: 31671232
[TBL] [Abstract][Full Text] [Related]
16. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
17. [In vitro antibiotic susceptibility to fluoroquinolones].
Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and causative organisms in microbial keratitis.
Green M; Apel A; Stapleton F
Cornea; 2008 Jan; 27(1):22-7. PubMed ID: 18245962
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance.
Kunimoto DY; Sharma S; Garg P; Rao GN
Ophthalmology; 1999 Jan; 106(1):80-5. PubMed ID: 9917785
[TBL] [Abstract][Full Text] [Related]
20. In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.
Kowalski RP; Kowalski TA; Shanks RM; Romanowski EG; Karenchak LM; Mah FS
Cornea; 2013 Jun; 32(6):830-4. PubMed ID: 23132444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
